Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Official Title

Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?

Brief Summary

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Detailed Description

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine
in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in
enhancing chloroquine effect.

Status

Completed

Conditions

COVID

Interventions

Drug: Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine
Other Name: alexoquine, chloroquine, hydroquine

Drug: zinc

Zinc tablets

Eligibility Criteria

Inclusion Criteria:

- Patients with positive COVID-19.

Exclusion Criteria:

- Contraindications or hypersensitivity to chloroquine.

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

Egypt

Locations

Tanta university hospital, Assuit University, Ainshams University
Tanta, Egypt

Investigators

sherief Abd-Elsalam, Ass. Prof., Principal Investigator
ass. Prof. Tropical Medicine

NCT Number

NCT04447534

MeSH Terms

Hydroxychloroquine

Chloroquine

Chloroquine diphosphate

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Tanta University

Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA